Patent: 7,951,788

Summary for Patent: 7,951,788

Title:	Method of treating cancer and other conditions or disease states using L-cytosine nucleoside analogs
Abstract:	The present invention relates to the use of the compound according to formula (I) Where S is (A) or (B); X is H or F; R.sup.1 is H, an acyl group, a C.sub.1-C.sub.20 alkyl or ether group, a phosphate, diphosphate, triphosphate or a phosphodiester group, a (C) or (D) group; Where Nu is a radical of a biologically active compound such as an anticancer, antihyperproliferative or antiviral compound such that an amino group or hydroxyl group from said biologically active agent forms a phosphate, phosphoramidate, carbonate or urethane group with the adjacent moiety; Each R.sup.8 is independently H, or a C.sub.1-C.sub.20 alkyl or ether group, preferably H or a C.sub.1-C.sub.2 alkyl group; k is 0-12, preferably, 0-2; R.sup.2 is H, an acyl group or a C.sub.1-C.sub.20 alkyl or ether group; and pharmaceutically acceptable salts, solvates or polymorphs thereof for the treatment of tumors, cancer and hyperproliferative diseases, among other conditions or disease states. ##STR00001##
Inventor(s):	Cheng; Yung-chi (Woodbridge, CT)
Assignee:	Yale University (New Haven, CT)
Application Number:	11/992,044
Patent Claims:	see list of patent claims

Details for Patent 7,951,788

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Recordati Rare Diseases, Inc.	ELSPAR	asparaginase	For Injection	101063	01/10/1978		2025-12-02
Merck Teknika Llc	TICE BCG	bcg live	For Injection	102821	06/21/1989		2025-12-02
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2025-12-02
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2025-12-02